Galderma, a Swiss skincare company, saw its stock price surge Thursday after reporting impressive annual sales growth of 17.7%. The company also issued optimistic projections for 2026 that exceeded analyst expectations.
Stock prices for Galderma, a Swiss-based skincare corporation, climbed Thursday morning following the company’s announcement of strong annual revenue performance and optimistic future projections.
The skincare giant reported annual revenue of $5.21 billion, representing a 17.7% increase from the previous year. The company’s Therapeutic Dermatology division led this impressive performance, with sales jumping more than 50% primarily due to its newly introduced Nemluvio treatment. This medication addresses chronic skin disorders including atopic dermatitis and prurigo nodularis.
Looking ahead to 2026, Galderma forecasts revenue growth between 17% and 20%, along with core profit margins reaching approximately 26% when calculated on a constant-currency basis.
By mid-morning trading, the company’s stock had climbed roughly 7%. Financial analysts from Vontobel noted that these projections surpassed market expectations, contributing to investor enthusiasm.
Nvidia Stops Making AI Chips for China Market, Report Says
Global Markets Mixed as Middle East Crisis Sparks Economic Uncertainty Debate
Former Star Entertainment Executives Found Guilty of Duty Violations
Middle East Conflict Disrupts Global Air Cargo, Stranding Goods Worldwide